Search Results
Your search for c matches 3834 pages
Showing 651 - 700Bispecific Antibodies and the Dawn of a New Era in Treatment of Multiple Myeloma
“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning!” —Steve Jobs Relapsed and refractory multiple myeloma remains a treatment challenge. Promising responses have been demonstrated with bispecific antibodies, with a...
How EQRx Aims to Reengineer the Health-Care System to Produce More Effective, Less Costly Cancer Drugs
The numbers are dizzying. The costs of cancer care in the United States are rising so fast that by 2030, it is projected the national cancer-attributable costs will total more than $246 billion, up from $183 billion in 2015—a 34% increase.1 And although the total global economic burden of cancer is ...
ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing
ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer.1 The updated guideline revisits recommendations from the 2015 guideline and addresses topics that have emerged since then in the move toward personalized medicine in metastatic...
Sylvester Researchers Receive $9.5 Million Grant to Study Esophageal Cancer
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have received a $9.5 million National Cancer Institute Program Project (P01) grant to investigate esophageal adenocarcinoma. “People with chronic gastroesophageal reflux disease can develop a...
Wall Street Doesn’t Believe in This Target
March 2, 2009. Just published in the Journal of Clinical Investigation.1 And we even got the cover. Twists and turns of heat shock protein-90 (Hsp90), the chaperone, the evolutionary capacitor. Great name and important cancer target. People smiled when I talked about this at the Hsp90 conference....
Concurrent Chemoradiation Therapy With Weekly Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
When combined with radiotherapy as definitive treatment of locally advanced head and neck squamous cell carcinoma, cisplatin at a dose of 40 mg/m2 weekly is noninferior to cisplatin at 100 mg/m2 every 3 weeks, according to the results of the ConCERT trial.1 These findings were presented by Atul...
Expert Point of View: Ryan B. Corcoran, MD, PhD
Ryan B. Corcoran, MD, PhD, commented on the C-800 study for The ASCO Post. Dr. Corcoran is the Mark J. Kusek Endowed Chair in Colorectal Cancer, Director of the Gastrointestinal Cancer Center Program and Scientific Director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital...
Activity Shown for Novel Immunotherapy Combination in Microsatellite-Stable Colorectal Cancer
Expanded data from the phase I C-800 study showed the immunotherapy combination of botensilimab and balstilimab appeared to be active in patients with microsatellite-stable (MSS) metastatic colorectal cancer. The findings were reported at the European Society for Medical Oncology (ESMO) World...
Primary Transoral Surgery and Reduced-Dose Adjuvant Radiation Therapy for HPV-Positive Locally Advanced Oropharyngeal Cancer
As reported in the Journal of Clinical Oncology by Robert L. Ferris, MD, PhD, and colleagues, the phase II ECOG-ACRIN E3311 trial has shown high progression-free survival rates and good functional outcomes in patients with intermediate-risk human papillomavirus (HPV; p16)-positive locally advanced...
Head and Neck Cancer 2021–2022 Almanac
Head and neck cancer is the seventh most common cancer in the world, with 1.1 million new diagnoses reported annually.1 In the United States, the incidence of oral and pharyngeal cancers is over 54,000 cases per year, resulting in over 11,000 yearly deaths.2 Although smoking and alcohol consumption ...
MRI-Guided Ultrasound Focal Therapy May Delay or Avoid Prostatectomy or Radiotherapy in Patients With Intermediate-Risk Prostate Cancer
MRI-guided focused ultrasound focal therapy produced “a high degree of success” and “a low rate of genitourinary adverse events” when used to treat select patients with intermediate-grade prostate cancer, Behfar Ehdaie, MD, MPH, and colleagues reported in The Lancet Oncology.1 Dr. Ehdaie is...
Dong Quai
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the herb dong...
Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up
Radiotherapy to the prostate in addition to standard treatment may improve survival for some men with advanced prostate cancer without detriment to quality of life, long-term study results from the STAMPEDE trial confirmed. These findings were published by Chris C. Parker, MD, and colleagues in...
Effect of Physical Activity on Disease-Free Survival in Patients Receiving Adjuvant Therapy for Stage III Colon Cancer
As reported in the Journal of Clinical Oncology by Brown et al, a prospective cohort study nested within the phase III CALGB/SWOG 80702/Alliance trial showed that greater volumes of physical activity in patients receiving adjuvant therapy for stage III colon cancer were associated with significant...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer
As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...
Epcoritamab Under Study in Difficult-to-Treat Large B-Cell Lymphoma
Subcutaneous epcoritamab, a bispecific antibody, has demonstrated deep and durable responses in a large expansion cohort of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to late-breaking data presented during the European Hematology Association (EHA) 2022 Congress in...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
Models to Assess Impact of Centralization of Specialist Cancer Services in England
In a study reported in The Lancet Oncology, Aggarwal et al identified the impact of several models of centralization of specialist cancer services in England, using rectal cancer surgery as an example. As stated by the investigators, “Centralization of specialist cancer services is occurring in...
ASCO-ACCC Recommendations to Reduce Barriers to Clinical Trial Enrollment
Here is a summary of the strategies developed by ASCO and the Association of Community Cancer Centers (ACCC) to increase participation by minority patients in cancer clinical trials and ensure greater equity, diversity, and inclusion in research studies. For a detailed list of the recommendations,...
Howard Sandler, MD, FASTRO, Voted President-Elect of ASTRO Along With Other New Officers
The members of the American Society for Radiation Oncology (ASTRO) elected seven new officers to the society’s Board of Directors, including Howard Sandler, MD, FASTRO, as President-Elect; Michael Kuettel, MD, PhD, MBA, FASTRO, as Secretary/Treasurer-Elect; Iris C. Gibbs, MD, FASTRO, and Curtiland...
Initiatives by Professional Oncology Organizations Focus on Improving Equitable Cancer Care
At the 2022 Summit on Cancer Health Disparities in Seattle, leaders from five of the leading professional societies in cancer discussed their respective organizations’ current initiatives toward improving cancer health disparities.1 Representatives from ASCO, the American Society for Clinical...
Expert Point of View: Rebecca A. Dent, MD
The invited discussant of the DS8201-A-U105 trial, Rebecca A. Dent, MD, Head of the Department of Medical Oncology, Senior Consultant, and Chief of the Breast Medical Oncology Service at the National Cancer Center Singapore, said the results were reassuring in terms of safety and may pave the way...
Nivolumab Plus T-DXd Under Study in HER2-Expressing Metastatic Breast Cancer
In the phase Ib DS8201-A-U105 trial, the addition of the PD-1 inhibitor nivolumab to the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) did not appear to improve outcomes over T-DXd alone (based on historical controls). However, it did establish the safety of the combination,...
Expert Point of View: Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, FACP, FASCO, the David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director of Gastrointestinal Oncology, and Co-Leader of the Gastrointestinal Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, told The ASCO Post she finds the data from...
MOUNTAINEER: Tucatinib Plus Trastuzumab Active in Metastatic Colorectal Cancer
In the phase II MOUNTAINEER trial, tucatinib in combination with trastuzumab produced durable responses in patients with previously treated HER2-positive metastatic colorectal cancer. The late-breaking data were presented at the European Society for Medical Oncology (ESMO) World Congress on...
Peter M. Voorhees, MD, Discusses Results From the ATLAS Trial
The invited discussant of the ATLAS trial, Peter M. Voorhees, MD, Professor of Medicine, Chief of the Plasma Cell Disorders Division, at Levine Cancer Institute and Atrium Health/Wake Forest Baptist in North Carolina, applauded the very good outcomes achieved in the study.1 However, he posed the...
Early Research Finds Link May Connect Cell-Signaling Pathway to Development of Esophageal Cancers, Barrett’s Esophagus
A team of researchers believe they have identified a cell-signaling pathway responsible for the development of esophageal adenocarcinomas, an aggressive type of esophageal cancer that has gradually become more common, even in younger people. Research published by Venkitachalam et al in...
New Poster Track at JADPRO Live Announced: APSHO Patient/Advocacy Perspective
Abstract submission is now open for JADPRO Live 2022, taking place October 20 to 23 in Aurora, Colorado, and includes a new poster track: APSHO Patient/Advocacy Perspective Posters. This track provides patients and patient advocates a platform to share perspectives on their care with over 1,500...
Study Reports Time-Limited Venetoclax-Based Regimens of Benefit in Front-Line Treatment of CLL
Time-limited venetoclax-based regimens provide deeper and more durable remissions than chemoimmunotherapy combinations in patients with previously untreated chronic lymphocytic leukemia (CLL), regardless of patients’ fitness, according to late-breaking data presented during the European Hematology...
Adjuvant Everolimus Narrowly Misses Statistical Significance in RCC, Except for Very High–Risk Patients
In the phase III EVEREST trial, adjuvant everolimus improved median recurrence-free survival in patients with resected renal cell carcinoma (RCC), but this finding failed to be statistically significant in the total study population of 1,499 patients, according to a prespecified boundary. However,...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
President Biden Appoints Cancer Panel Members, and Cancer Cabinet Unveils Priority Actions
On July 13, President Joe Biden announced his intent to appoint Mitchel Berger, MD; Carol Brown, MD; and Elizabeth M. Jaffee, MD, to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President to advise him...
Do Bone Marrow Biopsies Aid in Response Assessment for Patients With Follicular Lymphoma?
In a pooled analysis of patients with follicular lymphoma treated in National Clinical Trials Network trials reported in the Journal of Clinical Oncology, Rutherford et al found evidence that bone marrow biopsies can be avoided in response assessment. The investigators stated, “Bone marrow biopsies ...
Poziotinib Shows Activity in EGFR Exon 20–Mutant NSCLC, With Efficacy Dependent on Insertion Location
A phase II clinical trial of poziotinib for patients with non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 mutations found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may ...
Cautious Optimism About Mining for Patient-Centric Data
“If we have data, let’s look at it. If all we have are opinions, let’s go with mine.” —James Barksdale In this issue of The ASCO Post, Daniel Vorobiof, MD, and Irad Deutsch, principles at Belong.Life, a patient-oriented website whose self-described mission is to improve patient quality of life and ...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
Association of CTC Levels With Outcomes in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
In a study reported in the Journal of Clinical Oncology, Bertamini et al found that higher levels of circulating tumor cells (CTCs) at diagnosis were associated with poorer progression-free and overall survival in transplant-eligible patients with newly diagnosed multiple myeloma. The prognostic...
Analysis Finds Prevalence of Colorectal Cancer Screenings Remains Low in Younger Adults
In 2020, nearly 150,000 Americans, mostly those aged 50 and older, were diagnosed with colorectal cancer. However, about 18,000 of those individuals were younger than age 50. And while colorectal cancer rates have decreased for people over age 50, they have been increasing by 51% since 1994 for...
Direct-Acting Antivirals in HCV-Associated Indolent Non-Hodgkin Lymphomas
As reported in the Journal of Clinical Oncology by Merli et al, the Fondazione Italiana Linfomi phase II BArT study has shown that primary treatment of hepatitis C virus (HCV)-associated indolent non-Hodgkin lymphomas with direct-acting antivirals resulted in sustained virologic response in all...
Rucaparib Maintenance Improves Progression-Free Survival in Patients With Newly Diagnosed Advanced Ovarian Cancer Who Responded to Platinum-Based Therapy
Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib led to a significant improvement in progression-free survival compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy. The...
Is Focal Therapy With MRI-Guided Focused Ultrasound Safe and Effective for Grade Group 2 or 3 Prostate Cancer?
In a phase IIb study reported in The Lancet Oncology, Ehdaie et al found that focal ablation with magnetic resonance imaging (MRI)-guided focused ultrasound successfully treated a high proportion of patients with grade group 2 or 3 prostate cancer. As stated by the investigators, “Men with grade...
Children’s Cancer Cause Accepting Applications Through July 31 for 2022 Survivorship Champion’s Prize
The national advocacy group Children’s Cancer Cause, which plays a leadership role in advocacy and training on national issues affecting childhood cancer, has established an annual $10,000 award, the Survivorship Champion’s Prize, to be presented to a group, program, or institution making...
Early Transplant With Triplet Therapy May Delay Progression of Myeloma, but Individualized Approach Recommended
In the phase III DETERMINATION trial, progression-free survival was significantly improved with triplet induction therapy and early transplantation in newly diagnosed patients with multiple myeloma, but overall survival at 5 years was similar to the nontransplant approach.1 The findings were...
Ovarian Cancer: First-Line Every-3-Week Carboplatin/Paclitaxel vs Weekly Dose-Dense Regimens
As reported in The Lancet Oncology by Andrew R. Clamp, PhD, and colleagues, no significant differences in overall survival or updated progression-free survival were found with first-line treatment with weekly dose-dense regimens of carboplatin/paclitaxel vs every-3-week carboplatin/paclitaxel in...
Potential Association of the 2012 USPSTF Grade D Recommendation Against PSA Screening With Changes in Prostate Cancer–Specific Mortality
In a study reported in JAMA Network Open, Burgess et al found that the 2012 U.S. Preventive Services Task Force (USPSTF) Grade D recommendation against prostate-specific antigen (PSA) screening for all men appeared to be associated with ending of a trend of annual reductions in prostate...
Cemiplimab-rwlc Following Platinum-Based Chemotherapy in Recurrent or Metastatic Cervical Cancer: Clinical Implications
It is estimated that globally, more than 600,000 women per year are diagnosed with cervical cancer, and more than 300,000 die annually of the disease.1 Many women continue to be diagnosed with cervical cancer at an advanced stage, with a high risk of recurrence. To date, the most effective...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the BEGONIA trial,1 Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, called the activity of the combination of durvalumab and datopotamab deruxtecan (Dato-DXd) “notable,” with a 74% response rate overall,...
DESTINY-Breast03: Should Trastuzumab Deruxtecan Be the Preferred Second-Line Regimen in HER2-Positive Metastatic Breast Cancer?
Since the introduction of trastuzumab in the late 1990s, overall survival for patients with HER2-positive metastatic breast cancer has substantially improved. Median overall survival in the pivotal first-line trial was only 20.3 months in the chemotherapy arm, and 25.1 months in the...
